$XLRN Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in ACCELERON PHARMA INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in ACCELERON PHARMA INC. Get notifications about new insider transactions in ACCELERON PHARMA INC for free.
Page: < prev 1 ... 5 6 7 8 9 10 11 next >
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 10 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Buy | M | 3.88 | 6,700 | 25,996 | 6,700 | 0 to 6.7 K |
| Sep 10 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 24.90 | 3,300 | 82,170 | 0 | 3.3 K to 0 (-100.00 %) |
| Sep 10 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Buy | M | 3.88 | 3,300 | 12,804 | 3,300 | 0 to 3.3 K |
| Sep 10 2014 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Sell | S | 24.77 | 220 | 5,449 | 136,500 | 136.7 K to 136.5 K (-0.16 %) |
| Sep 10 2014 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Sell | S | 24.21 | 6,447 | 156,082 | 136,720 | 143.2 K to 136.7 K (-4.50 %) |
| Sep 10 2014 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Sell | S | 24.71 | 227 | 5,609 | 143,167 | 143.4 K to 143.2 K (-0.16 %) |
| Sep 10 2014 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Sell | S | 24.21 | 6,406 | 155,089 | 143,394 | 149.8 K to 143.4 K (-4.28 %) |
| Sep 10 2014 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Sell | S | 24.92 | 3,367 | 83,906 | 149,800 | 153.2 K to 149.8 K (-2.20 %) |
| Sep 10 2014 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Sell | S | 24.91 | 3,333 | 83,025 | 153,167 | 156.5 K to 153.2 K (-2.13 %) |
| Sep 04 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Option Exercise | M | 5.88 | 2,000 | 11,760 | 8,000 | |
| Sep 04 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 26.40 | 2,000 | 52,800 | 31,890 | 33.9 K to 31.9 K (-5.90 %) |
| Sep 04 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Buy | M | 5.88 | 2,000 | 11,760 | 33,890 | 31.9 K to 33.9 K (+6.27 %) |
| Sep 04 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Option Exercise | M | 1.80 | 4,000 | 7,200 | 6,496 | |
| Sep 04 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Sell | S | 25.79 | 1,000 | 25,790 | 27,500 | 28.5 K to 27.5 K (-3.51 %) |
| Sep 04 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Sell | S | 26.40 | 200 | 5,280 | 27,858 | 28.1 K to 27.9 K (-0.71 %) |
| Sep 04 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Sell | S | 25.80 | 3,800 | 98,040 | 28,058 | 31.9 K to 28.1 K (-11.93 %) |
| Sep 04 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Buy | M | 1.80 | 4,000 | 7,200 | 31,858 | 27.9 K to 31.9 K (+14.36 %) |
| Sep 04 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Option Exercise | M | 0.40 | 2,500 | 1,000 | 1,875 | |
| Sep 04 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Option Exercise | M | 5.08 | 7,500 | 38,100 | 18,750 | |
| Sep 04 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Sell | S | 26.43 | 2,500 | 66,075 | 52,656 | 55.2 K to 52.7 K (-4.53 %) |
| Sep 04 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Buy | M | 0.40 | 2,500 | 1,000 | 55,156 | 52.7 K to 55.2 K (+4.75 %) |
| Sep 04 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Sell | S | 26.44 | 7,500 | 198,300 | 52,656 | 60.2 K to 52.7 K (-12.47 %) |
| Sep 04 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Buy | M | 5.08 | 7,500 | 38,100 | 60,156 | 52.7 K to 60.2 K (+14.24 %) |
| Aug 26 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Option Exercise | M | 3.88 | 9,000 | 34,920 | 37,500 | |
| Aug 26 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Buy | M | 3.88 | 9,000 | 34,920 | 52,656 | 43.7 K to 52.7 K (+20.62 %) |
| Aug 19 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Sell | S | 30.00 | 500 | 15,000 | 28,500 | 29 K to 28.5 K (-1.72 %) |
| Aug 19 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Sell | S | 29.53 | 2,000 | 59,060 | 27,858 | 29.9 K to 27.9 K (-6.70 %) |
| Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Sell | S | 29.78 | 7,500 | 223,350 | 156,500 | 164 K to 156.5 K (-4.57 %) |
| Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Sell | S | 29.78 | 10,000 | 297,800 | 164,000 | 174 K to 164 K (-5.75 %) |
| Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | M | 3.88 | 7,000 | 27,160 | 175,751 | |
| Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | M | 3.88 | 3,000 | 11,640 | 182,751 | |
| Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 29.79 | 7,000 | 208,530 | 0 | 7 K to 0 (-100.00 %) |
| Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Buy | M | 3.88 | 7,000 | 27,160 | 7,000 | 0 to 7 K |
| Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 29.76 | 3,000 | 89,280 | 0 | 3 K to 0 (-100.00 %) |
| Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Buy | M | 3.88 | 3,000 | 11,640 | 3,000 | 0 to 3 K |
| Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 5.28 | 7,863 | 41,517 | 17,137 | |
| Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 5.28 | 3,137 | 16,563 | 9,873 | |
| Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 0.92 | 2,000 | 1,840 | 17,500 | |
| Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 30.02 | 11,000 | 330,220 | 0 | 11 K to 0 (-100.00 %) |
| Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 5.28 | 7,863 | 41,517 | 11,000 | 3.1 K to 11 K (+250.65 %) |
| Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 5.28 | 3,137 | 16,563 | 3,137 | 0 to 3.1 K |
| Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 29.79 | 2,000 | 59,580 | 0 | 2 K to 0 (-100.00 %) |
| Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 0.92 | 2,000 | 1,840 | 2,000 | 0 to 2 K |
| Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Option Exercise | M | 5.88 | 5,000 | 29,400 | 10,000 | |
| Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 30.00 | 7,000 | 210,000 | 31,890 | 38.9 K to 31.9 K (-18.00 %) |
| Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Buy | M | 5.88 | 5,000 | 29,400 | 38,890 | 33.9 K to 38.9 K (+14.75 %) |
| Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 29.85 | 2,000 | 59,700 | 33,890 | 35.9 K to 33.9 K (-5.57 %) |
| Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Option Exercise | M | 5.08 | 7,500 | 38,100 | 26,250 | |
| Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Option Exercise | M | 0.40 | 2,500 | 1,000 | 4,375 | |
| Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Sell | S | 30.37 | 100 | 3,037 | 43,656 | 43.8 K to 43.7 K (-0.23 %) |
| Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Sell | S | 29.77 | 7,400 | 220,298 | 43,756 | 51.2 K to 43.8 K (-14.47 %) |
| Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Buy | M | 5.08 | 7,500 | 38,100 | 51,156 | 43.7 K to 51.2 K (+17.18 %) |
| Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Sell | S | 29.78 | 2,500 | 74,450 | 43,656 | 46.2 K to 43.7 K (-5.42 %) |
| Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Buy | M | 0.40 | 2,500 | 1,000 | 46,156 | 43.7 K to 46.2 K (+5.73 %) |
| Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Option Exercise | M | 1.80 | 4,316 | 7,769 | 10,496 | |
| Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Option Exercise | M | 0.48 | 1,684 | 808 | 40,081 | |
| Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Sell | S | 29.82 | 1,500 | 44,730 | 29,000 | 30.5 K to 29 K (-4.92 %) |
| Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Sell | S | 30.25 | 100 | 3,025 | 29,858 | 30 K to 29.9 K (-0.33 %) |
| Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Sell | S | 29.77 | 5,900 | 175,643 | 29,958 | 35.9 K to 30 K (-16.45 %) |
| Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Buy | M | 1.80 | 4,316 | 7,769 | 35,858 | 31.5 K to 35.9 K (+13.68 %) |
| Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Buy | M | 0.48 | 1,684 | 808 | 31,542 | 29.9 K to 31.5 K (+5.64 %) |
| Aug 15 2014 | XLRN | ACCELERON PHARMA I ... | Maniatis Tom | Director | Gift | G | 0.00 | 40,000 | 0 | 184,431 | 224.4 K to 184.4 K (-17.82 %) |
| Aug 01 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Option Exercise | M | 3.88 | 8,000 | 31,040 | 46,500 | |
| Aug 01 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Buy | M | 3.88 | 8,000 | 31,040 | 43,656 | 35.7 K to 43.7 K (+22.44 %) |
| Aug 13 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Option Exercise | M | 1.80 | 8,000 | 14,400 | 14,812 | |
| Aug 13 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Buy | M | 1.80 | 8,000 | 14,400 | 29,858 | 21.9 K to 29.9 K (+36.60 %) |
| Jul 22 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Sell | S | 25.50 | 500 | 12,750 | 30,500 | 31 K to 30.5 K (-1.61 %) |
| Jul 22 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Sell | S | 26.78 | 33 | 884 | 11,858 | 11.9 K to 11.9 K (-0.28 %) |
| Jul 22 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Sell | S | 26.39 | 1,967 | 51,909 | 11,891 | 13.9 K to 11.9 K (-14.19 %) |
| Jul 25 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Option Exercise | M | 1.80 | 10,000 | 18,000 | 22,812 | |
| Jul 25 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Buy | M | 1.80 | 10,000 | 18,000 | 21,858 | 11.9 K to 21.9 K (+84.33 %) |
| Jul 16 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 5.28 | 3,000 | 15,840 | 13,010 | |
| Jul 16 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 0.92 | 2,000 | 1,840 | 19,500 | |
| Jul 16 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 30.12 | 3,000 | 90,360 | 0 | 3 K to 0 (-100.00 %) |
| Jul 16 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 5.28 | 3,000 | 15,840 | 3,000 | 0 to 3 K |
| Jul 16 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 29.71 | 900 | 26,739 | 0 | 900 to 0 (-100.00 %) |
| Jul 16 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 28.70 | 1,100 | 31,570 | 900 | 2 K to 900 (-55.00 %) |
| Jul 16 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 0.92 | 2,000 | 1,840 | 2,000 | 0 to 2 K |
| Jul 16 2014 | XLRN | ACCELERON PHARMA I ... | Kearney Terrence C | Director | Option Exercise | A | 28.37 | 20,000 | 567,400 | 20,000 | |
| Jul 11 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Option Exercise | M | 0.48 | 6,000 | 2,880 | 41,765 | |
| Jul 11 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Sell | S | 29.46 | 499 | 14,701 | 31,000 | 31.5 K to 31 K (-1.58 %) |
| Jul 11 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Sell | S | 28.77 | 1,001 | 28,799 | 31,499 | 32.5 K to 31.5 K (-3.08 %) |
| Jul 11 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Sell | S | 29.39 | 3,094 | 90,933 | 13,858 | 17 K to 13.9 K (-18.25 %) |
| Jul 11 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Sell | S | 28.55 | 2,906 | 82,966 | 16,952 | 19.9 K to 17 K (-14.63 %) |
| Jul 11 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Buy | M | 0.48 | 6,000 | 2,880 | 19,858 | 13.9 K to 19.9 K (+43.30 %) |
| Jul 09 2014 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Sell | S | 32.58 | 2,083 | 67,864 | 174,000 | 176.1 K to 174 K (-1.18 %) |
| Jul 09 2014 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Sell | S | 31.42 | 5,417 | 170,202 | 176,083 | 181.5 K to 176.1 K (-2.98 %) |
| Jul 09 2014 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Sell | S | 32.66 | 2,488 | 81,258 | 181,500 | 184 K to 181.5 K (-1.35 %) |
| Jul 09 2014 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Sell | S | 31.43 | 7,512 | 236,102 | 183,988 | 191.5 K to 184 K (-3.92 %) |
| Jul 09 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | M | 3.88 | 7,000 | 27,160 | 185,751 | |
| Jul 09 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | M | 3.88 | 3,000 | 11,640 | 192,751 | |
| Jul 09 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 32.59 | 1,800 | 58,662 | 0 | 1.8 K to 0 (-100.00 %) |
| Jul 09 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 31.42 | 5,200 | 163,384 | 1,800 | 7 K to 1.8 K (-74.29 %) |
| Jul 09 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Buy | M | 3.88 | 7,000 | 27,160 | 7,000 | 0 to 7 K |
| Jul 09 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 32.56 | 800 | 26,048 | 0 | 800 to 0 (-100.00 %) |
| Jul 09 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 31.40 | 2,200 | 69,080 | 800 | 3 K to 800 (-73.33 %) |
| Jul 09 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Buy | M | 3.88 | 3,000 | 11,640 | 3,000 | 0 to 3 K |
| Jul 02 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | A | 34.05 | 10,000 | 340,500 | 10,000 | |
| Jul 02 2014 | XLRN | ACCELERON PHARMA I ... | Maniatis Tom | Director | Sell | S | 34.41 | 1,561 | 53,714 | 224,431 | 226 K to 224.4 K (-0.69 %) |
| Jul 02 2014 | XLRN | ACCELERON PHARMA I ... | Maniatis Tom | Director | Sell | S | 33.87 | 39,439 | 1,335,799 | 225,992 | 265.4 K to 226 K (-14.86 %) |
| Jul 02 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 34.10 | 2,000 | 68,200 | 35,890 | 37.9 K to 35.9 K (-5.28 %) |
| Jul 02 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Option Exercise | M | 0.40 | 2,500 | 1,000 | 6,875 | |
| Jul 02 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Option Exercise | M | 5.08 | 7,500 | 38,100 | 33,750 | |
| Jul 02 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Sell | S | 34.10 | 2,500 | 85,250 | 35,656 | 38.2 K to 35.7 K (-6.55 %) |
| Jul 02 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Buy | M | 0.40 | 2,500 | 1,000 | 38,156 | 35.7 K to 38.2 K (+7.01 %) |
| Jul 02 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Sell | S | 34.09 | 7,500 | 255,675 | 35,656 | 43.2 K to 35.7 K (-17.38 %) |
| Jul 02 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Buy | M | 5.08 | 7,500 | 38,100 | 43,156 | 35.7 K to 43.2 K (+21.03 %) |
| Jun 27 2014 | XLRN | ACCELERON PHARMA I ... | George Jean | Director | Sell | S | 35.01 | 10,320 | 361,303 | 1,903,063 | 1.9 M to 1.9 M (-0.54 %) |
| Jun 27 2014 | XLRN | ACCELERON PHARMA I ... | George Jean | Director | Sell | S | 35.00 | 171 | 5,985 | 1,913,383 | 1.9 M to 1.9 M (-0.01 %) |
| Jun 24 2014 | XLRN | ACCELERON PHARMA I ... | George Jean | Director | Sell | S | 35.03 | 10,402 | 364,382 | 1,913,554 | 1.9 M to 1.9 M (-0.54 %) |
| Jun 24 2014 | XLRN | ACCELERON PHARMA I ... | George Jean | Director | Sell | S | 35.27 | 13,618 | 480,307 | 1,923,956 | 1.9 M to 1.9 M (-0.70 %) |
| Jun 24 2014 | XLRN | ACCELERON PHARMA I ... | George Jean | Director | Sell | S | 35.02 | 1,457 | 51,024 | 1,937,574 | 1.9 M to 1.9 M (-0.08 %) |
| Jun 24 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Option Exercise | M | 5.88 | 5,000 | 29,400 | 15,000 | |
| Jun 24 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 35.00 | 7,000 | 245,000 | 37,890 | 44.9 K to 37.9 K (-15.59 %) |
| Jun 24 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Buy | M | 5.88 | 5,000 | 29,400 | 44,890 | 39.9 K to 44.9 K (+12.53 %) |
| Jun 20 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Sell | S | 34.13 | 500 | 17,065 | 32,500 | 33 K to 32.5 K (-1.52 %) |
| Jun 20 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Sell | S | 34.49 | 2,000 | 68,980 | 13,858 | 15.9 K to 13.9 K (-12.61 %) |
| Jun 19 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Option Exercise | M | 3.88 | 8,000 | 31,040 | 54,500 | |
| Jun 19 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Buy | M | 3.88 | 8,000 | 31,040 | 35,656 | 27.7 K to 35.7 K (+28.93 %) |
| Jun 17 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | VP General Counsel ... | Option Exercise | M | 5.28 | 2,740 | 14,467 | 16,010 | |
| Jun 17 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | VP General Counsel ... | Option Exercise | M | 3.88 | 4,260 | 16,529 | 51,240 | |
| Jun 17 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | VP General Counsel ... | Option Exercise | M | 0.92 | 2,000 | 1,840 | 21,500 | |
| Jun 17 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | VP General Counsel ... | Sell | S | 34.13 | 2,700 | 92,151 | 0 | 2.7 K to 0 (-100.00 %) |
| Jun 17 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | VP General Counsel ... | Sell | S | 33.86 | 6,300 | 213,318 | 2,700 | 9 K to 2.7 K (-70.00 %) |
| Jun 17 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | VP General Counsel ... | Buy | M | 5.28 | 2,740 | 14,467 | 9,000 | 6.3 K to 9 K (+43.77 %) |
| Jun 17 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | VP General Counsel ... | Buy | M | 3.88 | 4,260 | 16,529 | 6,260 | 2 K to 6.3 K (+213.00 %) |
| Jun 17 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | VP General Counsel ... | Buy | M | 0.92 | 2,000 | 1,840 | 2,000 | 0 to 2 K |
| Jun 13 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Option Exercise | M | 0.48 | 6,000 | 2,880 | 47,765 | |
| Jun 13 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Sell | S | 33.25 | 1,500 | 49,875 | 33,000 | 34.5 K to 33 K (-4.35 %) |
| Jun 13 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Sell | S | 33.23 | 6,000 | 199,380 | 15,858 | 21.9 K to 15.9 K (-27.45 %) |
| Jun 13 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Buy | M | 0.48 | 6,000 | 2,880 | 21,858 | 15.9 K to 21.9 K (+37.84 %) |
| Jun 11 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | M | 3.88 | 7,000 | 27,160 | 195,751 | |
| Jun 11 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | M | 3.88 | 3,000 | 11,640 | 202,751 | |
| Jun 11 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 31.98 | 4,197 | 134,220 | 0 | 4.2 K to 0 (-100.00 %) |
| Jun 11 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 31.16 | 2,803 | 87,341 | 4,197 | 7 K to 4.2 K (-40.04 %) |
| Jun 11 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Buy | M | 3.88 | 7,000 | 27,160 | 7,000 | 0 to 7 K |
| Jun 11 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 32.00 | 1,686 | 53,952 | 0 | 1.7 K to 0 (-100.00 %) |
| Jun 11 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 31.17 | 1,314 | 40,957 | 1,686 | 3 K to 1.7 K (-43.80 %) |
| Jun 11 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Buy | M | 3.88 | 3,000 | 11,640 | 3,000 | 0 to 3 K |
| Jun 11 2014 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Sell | S | 31.99 | 2,800 | 89,572 | 191,500 | 194.3 K to 191.5 K (-1.44 %) |
| Jun 11 2014 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Sell | S | 31.19 | 2,200 | 68,618 | 194,300 | 196.5 K to 194.3 K (-1.12 %) |
| Jun 11 2014 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Sell | S | 31.98 | 6,109 | 195,366 | 196,500 | 202.6 K to 196.5 K (-3.02 %) |
| Jun 11 2014 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Sell | S | 31.14 | 3,891 | 121,166 | 202,609 | 206.5 K to 202.6 K (-1.88 %) |
| Jun 04 2014 | XLRN | ACCELERON PHARMA I ... | Polaris Venture Management Co ... | 10% Owner | Sell | J | 0.00 | 198,005 | 0 | 2,621,738 | 2.8 M to 2.6 M (-7.02 %) |
| Jun 04 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 29.72 | 2,000 | 59,440 | 39,890 | 41.9 K to 39.9 K (-4.77 %) |
| Jun 04 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Option Exercise | M | 0.40 | 2,500 | 1,000 | 9,375 | |
| Jun 04 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Option Exercise | M | 5.08 | 7,500 | 38,100 | 41,250 | |
| Jun 04 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Buy | S | 29.73 | 2,500 | 74,325 | 27,656 | 25.2 K to 27.7 K (+9.94 %) |
| Jun 04 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Buy | M | 0.40 | 2,500 | 1,000 | 30,156 | 27.7 K to 30.2 K (+9.04 %) |
| Jun 04 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Sell | S | 30.04 | 200 | 6,008 | 27,656 | 27.9 K to 27.7 K (-0.72 %) |